Reni Benjamin: Got it. And then what about for non-small cell?
Jay Short: On the non-small cell side, I’ll just add and jump in here for a second. As you noticed, we mentioned that we’re doing any targeted population, which is a significant large population, but it’s a subset of all non-small cell lung cancer patients. And we’re going to talk a bit more about that in a future conference. But at the moment, we’re just simply keeping that at a high level at this point.
Reni Benjamin: Got it. Okay. And just maybe just going back to Eric’s answer just in regards to the 14.2 mgs per kg, significantly higher than what’s been evaluated prior, do we have a sense as to kind of the PK/PD at this point? And how much sort of receptor occupancy or blocking we’re already getting? Any sort of color there would be helpful.
Jay Short: Eric, I’ll just jump in for a moment. I think that a lot of the studies that were done prior with ipilimumab have shown that you do continue to get an advantage up to 10 mgs per kg. We don’t have the data of 14.2 mgs per kg, but we’ll definitely be comparing the 10 to the 14.2 and our belief is we may not quite have saturated it yet at the 10, but the data is pretty clear when you compare one going one, three and up to 10 mgs per kg that you continue to get benefit. So I think, though, your point — it’s a reasonable question though. At what point does that efforts start become saturated. And I think certainly, there’s plenty of the incentive to check out this one gram level. And we will hope to report out on that in the future.
Eric Sievers: And Ren maybe I’ll jump in here with your question about the PK. So as these are conditionally binding antibodies, we would need to do tumor biopsies to explore a receptor occupancy because the antibody was designed to explicitly not bind in the periphery. So it turns out to be a more challenging question to answer and one that we haven’t done those biopsies in humans to characterize receptor occupancy. And then your question about PK is that it is really behaving in a pretty standard manner. There are really no PK surprises to date.
Reni Benjamin: Excellent. Thanks guys for taking the questions.
Eric Sievers: Thank you.
Operator: Thank you. There are no further questions at this time. I would like to turn the floor back over to Jay Short for any closing comments.
Jay Short: Thanks, everyone, for your attention, and we’re looking forward to a very exciting second quarter. We’ll be talking to you soon. Thank you.
Operator: This concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.
